KCT0005173
Recruiting
未知
Investigating treatment response and immune profile in association with pattern identification in NSCLC patients scheduled for immune checkpoint inhibitor monotherapy (HARMONY study): A protocol for a prospective observational study
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Korea Institute of Oriental Medicine
- Enrollment
- 200
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients diagnosed with stage IIIB, IIIC, IV (TNM 8th edition) non\-small cell lung cancer
- •2\. Patients scheduled to be treated for immune checkpoint inhibitor (Pembrolizumab, Atezolizumab) monotherapy for secondary or higher line therapy after platinum\-based primary therapy has been failed
- •3\. Patients over 6 months survival expected
- •4\. Patients with ECOG scale (ECOG\-PS) 0\-2
- •5\. Patients who voluntarily participate to this clinical study with written informed consent
Exclusion Criteria
- •1\. Patients having active brain metastases with clinically significant neurological symptoms or signs
- •2\. Patients diagnosed with other malignancies within 5 years which may influence non\-small cell lung cancer
- •3\. Patients having autoimmune disease
- •4\. Pregnant woman or lactating woman
- •5\. Patients considered to be unsuitable to participate in this study by the investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Evaluation of treatment response for immune checkpoint inhibitors in non-small cell lung cancer patients using [18F]F-AraG PET/CTJPRN-jRCTs051220109akamoto Yuji60
Completed
Not Applicable
To evaluate effect of immunotherapy .Health Condition 1: - Health Condition 2: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxCTRI/2024/02/062655HCG NCHRI Cancer Centre10
Completed
Phase 4
Treatment response of spirulina, omega-3 fatty acid and Vitamin E & C in OSMFHealth Condition 1: - Health Condition 2: K135- Oral submucous fibrosisCTRI/2020/10/028530Maulana Azad Institute of Dental Sciences60
Completed
Not Applicable
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy SubjectJPRN-UMIN000045492Shionogi & Co., Ltd.143
Recruiting
Phase 2
Efficacy stem cells in improving the symptoms of patients with lupusIRCT20130812014333N182Kermanshah University of Medical Sciences20